# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Frazier (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX004-SYN-TD
- Date: 2008-02-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing primary care for type 2 diabetes and high blood pressure above goal: A1c, kidney function, urine albumin, lipids, the yearly liver check with FIB-4, eyes, feet and brain health in a former professional boxer. **S**

## Objective

Hemoglobin A1c: 8.4% (high); Glucose (fasting): 168 mg/dL (high); Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 1.08 mg/dL; eGFR (CKD-EPI 2003, no race term): 77 mL/min/1.73 m²; Urine albumin-to-creatinine ratio: 18 mg/g; Total cholesterol: 212 mg/dL (high); LDL cholesterol: 132 mg/dL (high); HDL cholesterol: 38 mg/dL (low); Triglycerides: 210 mg/dL (high); AST: 48 U/L (high); ALT: 42 U/L; Alkaline phosphatase: 96 U/L; Albumin: 4 g/dL; Total bilirubin: 0.9 mg/dL; Hemoglobin: 14.2 g/dL; Platelets: 138 10*3/uL (low); Vitamin B12: 340 pg/mL; PHQ-9: 4; AUDIT-C: 2. All results are synthetic.

BP 152/92 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 104 kg; BMI 31.4 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes; Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure; Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated; Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin; Obesity, class 1 (BMI 31.4); Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years **S**
- Started: Lisinopril 20 mg oral tablet, one tablet daily; taken for years **S**
- Started: Atorvastatin 40 mg oral tablet, one tablet daily **S**

## Plan

- Diabetes: continue metformin, an A1c every three months until at goal and then every six months, diabetes self-management education, a vitamin B12 check on long-term metformin, and no medicine that causes low blood sugar. Guideline: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Hepatology consultation for a high FIB-4 with mildly low platelets, with transient elastography and a liver ultrasound the same day. Guideline: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023) **S**
- Liver assessment: FIB-4 from the yearly liver tests, then transient elastography if FIB-4 is 1.3 or higher; hepatitis B, hepatitis C and HIV tests, iron studies, and an alcohol history. Guideline: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Blood pressure: a validated home monitor with a large cuff, readings twice a day for a week, a goal below 130/80 mmHg, and less salt. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks; a baseline ECG; aspirin for primary prevention not used because of bleeding risk. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Kidneys: eGFR by the race-free CKD-EPI 2003 equation and urine albumin-to-creatinine ratio at least yearly, and potassium and creatinine on lisinopril. Guideline: 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Eyes and feet: a dilated eye examination at the eye clinic, a comprehensive foot examination yearly, daily foot checks and callus care. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026) **S**
- Brain health: a documented cognitive screen at the preventive visit, blood pressure and glucose control, sleep, hearing and mood checks, and an honest conversation that chronic traumatic encephalopathy cannot be diagnosed during life. Guideline: National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Cost and access: low-cost generics, 90-day supplies, and help with coverage for any brand-name medicine. Guideline: 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026) **S**
